Astria Therapeutics Inc. has released its financial results for the first quarter ended March 31, 2025. The company reported a net loss of $33.7 million for the quarter, an increase from the $19.9 million net loss reported for the same period in 2024. The net loss per share was $0.58, compared to a net loss per share of $0.38 in the first quarter of 2024. The company had cash, cash equivalents, and short-term investments totaling $295.1 million as of March 31, 2025, down from $328.1 million at the end of 2024. Astria expects this cash position to be sufficient to fund its operations into mid-2027, supporting various program activities including the ALPHA-ORBIT Phase 3 trial for navenibart and the completion of the Phase 1a clinical trial for STAR-0310. In terms of business updates, Astria is currently enrolling patients in the pivotal Phase 3 ALPHA-ORBIT trial evaluating navenibart (STAR-0215) for hereditary angioedema. The company anticipates results from the ALPHA-SOLAR Long-Term Extension Trial in mid-2025 and results from the Phase 1a STAR-0310 healthy subject trial in the third quarter of 2025. Additionally, Astria announced its participation in upcoming investor conferences, including the Jefferies Global Healthcare Conference and the Oppenheimer Innovators in I&I Summit, both taking place in June 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.